User: "yeah actually you're right, lets do those" (MEDP + RGEN — the Tier-1 laggards the user does NOT own). Both Massive-financials-backed, lint clean, projected.

• MEDP (2026-06-04-medp-deep-dive.md, conviction HIGH — the standout): the lane's best risk/reward. Highest-quality CRO, founder-led, ZERO debt, ~20% op margins (industry-leading), and fundamentals ACCELERATING through the funding winter — revenue +26.5% YoY (Q1'26 $707M vs $559M), ~$15.9 TTM EPS. Yet −27% off high at ~28× P/E (PEG ~1.1). The de-rate is multiple compression on funding-winter FEAR that MEDP's own P&L refutes. Direct proxy for domino #3 (CRO book-to-bill). Entry ~$420-460, stop ~$370, target $560-630 on re-rate. Risk = the multiple, not the business.
• RGEN (2026-06-04-rgen-deep-dive.md, conviction medium): quality bioprocessing pure-play recovering from a REAL post-COVID destocking trough (Q4'24 net loss −$34M, GM collapsed to 23%) — now rev +15% YoY, GM rebuilt to ~56%, profitable again, but op margin (8-9%) still far below historical ~20% (the recovery runway). Still expensive (~9× sales, GAAP P/E ~140× amort-distorted) even after −28% off high. Bioprocessing = the LATEST domino (#5), so catalyst is further out than MEDP. Quality-recovery, not value. Entry ~$115-130, stop ~$105, target $160-176.
• Verdict: MEDP > RGEN on risk/reward — cheaper, faster-growing, no debt, earlier-cycle catalyst. MEDP is now the lane's single highest-conviction name (and a clean answer to "what do I buy that hasn't run").
• 4 deep dives now built for the lane: ABCL, GENB (app-layer barbell) + MEDP, RGEN (laggard quality). Standout = MEDP.